PT2009025E - Método de inibição da actividade dos osteoclastos - Google Patents

Método de inibição da actividade dos osteoclastos Download PDF

Info

Publication number
PT2009025E
PT2009025E PT08015570T PT08015570T PT2009025E PT 2009025 E PT2009025 E PT 2009025E PT 08015570 T PT08015570 T PT 08015570T PT 08015570 T PT08015570 T PT 08015570T PT 2009025 E PT2009025 E PT 2009025E
Authority
PT
Portugal
Prior art keywords
receptors
osteoclast activity
inhibiting osteoclast
isolated
disclosed
Prior art date
Application number
PT08015570T
Other languages
English (en)
Inventor
Dirk M Anderson
Laurent J Galibert
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of PT2009025E publication Critical patent/PT2009025E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT08015570T 1998-05-14 1999-05-13 Método de inibição da actividade dos osteoclastos PT2009025E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8548798P 1998-05-14 1998-05-14
US11083698P 1998-12-03 1998-12-03

Publications (1)

Publication Number Publication Date
PT2009025E true PT2009025E (pt) 2011-09-19

Family

ID=26772773

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08015570T PT2009025E (pt) 1998-05-14 1999-05-13 Método de inibição da actividade dos osteoclastos

Country Status (12)

Country Link
US (2) US20050089522A1 (pt)
EP (2) EP1076699B1 (pt)
JP (1) JP2002514418A (pt)
AT (2) ATE517916T1 (pt)
AU (1) AU762574B2 (pt)
CA (1) CA2328140C (pt)
CY (1) CY1111912T1 (pt)
DE (1) DE69939822D1 (pt)
DK (1) DK2009025T3 (pt)
ES (1) ES2317694T3 (pt)
PT (1) PT2009025E (pt)
WO (1) WO1999058674A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
ATE399861T1 (de) * 1996-12-13 2008-07-15 Schering Corp Oberflächenantigene aus säugern
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
CA2257247C (en) 1997-04-15 2012-09-11 Snow Brand Milk Products Co., Ltd. Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
SI0975754T2 (sl) * 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
JP4790179B2 (ja) * 1999-07-28 2011-10-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞活性を阻害する方法
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002064782A2 (en) * 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
EA200301041A1 (ru) * 2001-03-22 2004-08-26 Барнс-Джуиш Хоспитал Стимуляция остеогенеза с использованием гибридных белков лиганда для rank
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
WO2002092016A2 (en) * 2001-05-17 2002-11-21 Immunex Corporation Therapeutic use of rank antagonists
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP1442297A4 (en) * 2001-10-12 2004-12-15 Barnes Jewish Hospital METHOD FOR SCREENING OSTEOGENIC COMPOUNDS
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
WO2008150025A1 (ja) * 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. 新しい骨量増加薬
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DK0667901T4 (da) 1991-10-25 2008-11-10 Immunex Corp Hidtil ukendt cytokin
DK0672141T3 (da) * 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
PT832229E (pt) * 1995-06-07 2004-06-30 Immunex Corp Muteina de cd40l
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
ATE399861T1 (de) 1996-12-13 2008-07-15 Schering Corp Oberflächenantigene aus säugern
WO1998028423A2 (en) 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
JP4138013B2 (ja) * 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2257247C (en) * 1997-04-15 2012-09-11 Snow Brand Milk Products Co., Ltd. Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
SI0975754T2 (sl) 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
EP0980432A1 (en) 1997-05-01 2000-02-23 Amgen, Inc. Chimeric opg polypeptides
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
EP1140136B1 (en) 1999-09-03 2007-05-16 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
MXPA02008144A (es) 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

Also Published As

Publication number Publication date
CA2328140A1 (en) 1999-11-18
US20090004196A1 (en) 2009-01-01
WO1999058674A3 (en) 2000-02-10
WO1999058674A2 (en) 1999-11-18
EP1076699A2 (en) 2001-02-21
CA2328140C (en) 2012-03-13
US7790684B2 (en) 2010-09-07
US20050089522A1 (en) 2005-04-28
DK2009025T3 (da) 2011-11-14
CY1111912T1 (el) 2015-11-04
EP2009025B1 (en) 2011-07-27
ATE517916T1 (de) 2011-08-15
ATE412746T1 (de) 2008-11-15
AU3988899A (en) 1999-11-29
EP1076699B1 (en) 2008-10-29
EP2009025A1 (en) 2008-12-31
AU762574B2 (en) 2003-06-26
ES2317694T3 (es) 2009-04-16
JP2002514418A (ja) 2002-05-21
DE69939822D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
IL139355A0 (en) 24-hydroxyvitamin d, analogs and uses thereof
PL347469A1 (en) Use of certain drugs for treating nerve root injury
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2000015205A3 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
PL346143A1 (en) Tan-1057 derivatives
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
HUP0000954A3 (en) Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
IT1283589B1 (it) Procedimento per il trattamento di rifiuti solidi urbani e assimilati, nonche' impianto per la realizzazione del procedimento
HUP0101602A2 (hu) Termékenységet javító készítmény, és annak alkalmazása
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
FR2745179B1 (fr) Melange maitre actif pour la preparation d'une composition dermocosmetique, composition dermocosmetique contenant ce melange, et methode pour la preparation de ce melange